BioSpace News Archive

Saranas, Inc., developer of the Early Bird® Bleed Monitoring System for the monitoring and early detection of internal bleed complications during endovascular procedures, announced the online publication of two peer-reviewed articles highlighting the system’s accuracy and performance.

IntelGenx Corp. announced that Health Canada has authorized the sale of IntelGenx’s hand sanitizer product, both in liquid and gel formulations, which will be manufactured using excess capacity at the Company’s Health Canada-certified cGMP manufacturing facility in Montreal.

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigati

- A one-year internship program for recent graduates that will provide work experience and training - - Internships in all departments from research through commercialization - - B.S., M.S., Pharm.D., MBA, Ph.D., M.D., and J.D. graduates are all welcome to apply -

Orpheris , a subsidiary of Ashvattha Therapeutics , a biotech company focused on developing novel dendrimer-based therapies to treat unmet medical needs in inflammatory, oncology, and ocular diseases, today announced results from a Phase 1 single administration study evaluating the subcutaneous (SC) formulation of OP-101 (4 or 8 mg/kg) in healthy volunteers. This press release features multimedia. View the full

Addition of sFlt-1 for second and third trimester pre-eclampsia management rounds out portfolio

MYR Pharmaceuticals, a German biotechnology company focused on the development and commercialization of therapeutics for the treatment of chronic hepatitis B and D, is pleased to announce the establishment of its wholly owned subsidiary MYR Pharmaceuticals France SAS, located in Paris (France) . Today, around 15-20 million peo

Data show the clinical activity of ABBV-3373 and support advancing the development of the platform in rheumatoid arthritis and initiating clinical studies in other immune-mediated diseases[1]

Scipher Medicine, a pioneer in integrating network science with molecular data to match individual patients with the most effective therapies, has appointed Jerry Conway as Senior Vice President of Market Access. He will focus on patient access to Scipher’s precision diagnostic tools beginning with PrismRA®, a first-of-its-kind molecular signature test that predicts non-response to anti-TNFs for patients with rheumatoid a

ApiFix, the only posterior motion-preserving scoliosis correction technology available in the U.S., provides unique advantages for treating progressive adolescent idiopathic scoliosis